Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20
- The P-II study involves assessing of Bavencio in 15 women (median age 34yrs.) with GTT that are resistant to mono-CT. All patients had progressed on treatment with MTX; one patient had progressed on actinomycin-D. while patients received Bavencio until hCG levels returned to normal, followed by 3 additional cycles
- Results: 8/15 patients had no sign of disease relapse @29mos. follow-up. & hCG levels returned to normal and have been maintained, if disease has not relapsed @12mos. & monitoring of hCG has concluded, the patient is considered cured, Bavencio showed resistance in the remaining 7 patients (47%), requiring CT with actinomycin-D/ polychemotherapy with/out surgery
- The study suggested that Bavencio may work as a potential therapy for GTT patients. The study is the first study exploring use of immunotherapy in patients with GTT
Click here to read full press release/ article | Ref: ASCO | Image: CHE Manager